A phase I/II trial of beta-(1,3)/(1,6) D-glucan in the treatment of patients with advanced malignancies receiving chemotherapy
2008

Study of Beta-Glucan in Cancer Patients

Sample size: 20 publication Evidence: low

Author Information

Author(s): Alan B Weitberg

Primary Institution: Roger Williams Medical Center and Boston University School of Medicine

Hypothesis

Can beta-(1,3)/(1,6) D-glucan improve blood counts and be safely administered to patients with advanced malignancies receiving chemotherapy?

Conclusion

Beta-glucan is well-tolerated in cancer patients receiving chemotherapy and may improve blood counts.

Supporting Evidence

  • No new symptoms were reported by patients while taking beta-glucan.
  • 60% of patients felt a sense of well-being while on beta-glucan.
  • 40% of patients reported less fatigue during chemotherapy while taking beta-glucan.
  • There was a trend of improved blood counts during the study compared to pre-study counts.

Takeaway

This study tested a substance called beta-glucan in cancer patients to see if it helps their blood counts and if it's safe to use.

Methodology

Twenty patients received beta-glucan and were monitored for side effects and blood counts over six months.

Limitations

The study was uncontrolled and had a small sample size.

Participant Demographics

Patients were aged 38 to 84, with an equal number of males and females.

Digital Object Identifier (DOI)

10.1186/1756-9966-27-40

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication